Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
119.31
+2.16 (1.84%)
At close: Feb 11, 2026, 4:00 PM EST
119.13
-0.18 (-0.15%)
After-hours: Feb 11, 2026, 4:47 PM EST
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2024. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$866,813
Profits / Employee
$243,387
Market Cap
296.13B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Novartis AG | 75,267 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| AbbVie | 55,000 |
MRK News
- 10 hours ago - KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment - Business Wire
- 1 day ago - Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform - Business Wire
- 2 days ago - Merck: The Spike Doesn't Make It Overvalued - Seeking Alpha
- 2 days ago - Merck: A Buy For 2026, But The Clock Is Still Ticking - Seeking Alpha
- 2 days ago - From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade) - Seeking Alpha
- 2 days ago - Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum - Seeking Alpha
- 8 days ago - Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow - Benzinga